Clinigen Group opens office in Tokyo, expands in JapanStaff Writer | October 18, 2016
Clinigen Group, a global pharmaceuticals and services company, has extended its geographical reach to Japan with the opening of a new office in Tokyo.
Expansion Foscavir treats cytomegalovirus
Its presence in the region will also allow the firm to take over the marketing authorisation for its lead specialty pharmaceutical (SP) product Foscavir from Nobel Pharma, who has distributed the product in Japan for the company since 2011.
Foscavir treats cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) or Cytomegalovirus viremia and cytomegalovirus disease in hematopoietic stem cell transplant (HSCT) patients.
With more than 2,000 patients are treated annually with the drug, Japan is an important market for the firm. The region is also the second largest pharmaceutical market in the world. ■